CS1001 for Extranodal Lymphoma

"According to the prerequisites for this experiment, potential participants must be aged 18 or over and under 75."

"At present, there are 7 active trials conducting research on CS1001 with 4 of them now in Phase 3. While a handful of the experiments for CS1001 take place in Guangzhou, Guangdong, 8 different places around the world have studies dedicated to this medication."

"This clinical trial is searching for 80 individuals, between 18 and 75 years of age, diagnosed with relapsed or refractory t-cell lymphoma. Furthermore, candidates must have an Eastern Cooperative Oncology Group performance status of 0 or 1; evaluable/measurable lesions per Lugano 2014 classification; adequate organ/bone marrow function sans severe hematopoietic disorder as well as no heart/lungs/liver/kidney dysfunction nor immune deficiency. Prior anti-cancer treatments should also be recovered to baseline toxicity levels ≤ Grade 1 according to CTCAE v4.03 standards."

"Presently, 7 ongoing studies are in progress for CS1001 across 4 cities and 2 nations. The first trial commenced back in 2018 under the sponsorship of CStone Pharmaceuticals with 80 participants, ultimately reaching its Phase 2 approval benchmark. Since then, an additional four trials have concluded their research activities."

"Unfortunately, this clinical trial is no longer recruiting new participants. It was initially posted on June 12th 2018 and the last update occurred on October 30th 2022. If you are seeking alternate trials, there are 1732 studies in search of patients with lymphoma or t-cell cancers as well as 7 active trials for CS1001 enrolling volunteers."

"Our internal assessment at Power puts the safety of CS1001 is a 2 as this Phase 2 trial does not have evidence supporting efficacy but there are multiple rounds of data demonstrating its security."

"Currently, this medical trial is not enrolling patients. Initially posted on June 12th 2018 and last updated October 30th 2022, potential participants should look elsewhere for an open clinical trial. The database currently lists 1732 active trials related to lymphoma t-cell and 7 studies which are actively seeking enrolment of CS1001."